In a rat model of TNBS colitis, the combination of TRPV1 antagonist BCTC and TRPA1 antagonist TCS-5861528 was found to significantly reduce visceral hypersensitivity when compared to the injection of the compounds separately, indicating a synergistic effect [70]. This evidence concerns the gene TRPV1 and colitis.